Drug Pipeline Reports Now Available

Our bi-annual Drug Pipeline Reports provide updates about investigational, specialty and generic drugs. WellDyneRx closely monitors the drug development pipeline for upcoming brand, specialty, generic and biosimilar drug approvals. Given the year-over-year increase in drug costs, this vigilance allows WellDyneRx to develop and implement cost-containment strategies to prevent our clients and members from experiencing unexpectedly high drug costs.

Each report contains:

  • Descriptions of newly approved drugs, including product highlights, place in therapy, and market impact.
  • Drug summaries with anticipated FDA approval dates in the upcoming 12 months.
  • Additional FDA actions, including rejections and indications for specific drugs.

Access our current Drug Pipeline reports now:

Biosimilar Drug Pipeline Report
Brand Drug Pipeline Report
Generic Drug Pipeline Report
Specialty Drug Pipeline Report

For questions, please contact your Account Executive


2018 Quarter Three WellInformed Table Contents